Posted by Michael Wonder on 17 May 2018
EU OKs first-line use of Ipsen’s Cabometyx
17 May 2018 - The European Commission has approved Ipsen/Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma.
The approval rides on the back of data from the CABOSUN trial, which showed that Cabometyx (cabozantinib) prolongs progression-free survival (PFS) in treatment-naive advanced renal cell carcinoma patients with intermediate- or poor-risk disease.
According to the findings, patients given Cabonetyx had a median PFS of 8.6 months versus 5.3 months for those treated initially with sunitinib (Pfizer’s Sutent), marking a 52% reduction in the hazard for progression or death.
